Mielóma multiplex: nyitott vizsgálatok itt: Németország
64 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. nov. 10.. Ask the study team whether a trial fits you.
3. fázisToborozTrial-stage medicine
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
- Where
- Hamburg, Lübeck, Tuebingen
- Age
- 18 év and over
- People
- 410 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT05730036EU 2022-501396-62-00Regiszter frissítve: 2026-11-06
1/2. fázisToborozTrial-stage medicine
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
- Where
- Hamburg, Leipzig
- Age
- 18 év and over
- People
- 200 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05583617EU 2023-504484-16-00Regiszter frissítve: 2026-11-05
2. fázisToborozTrial-stage medicine
Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma
- Where
- Berlin, Bonn, Chemnitz, Cologne, Dresden, Erlangen, Essen, Greifswald, Hamburg, Hanover, Heidelberg, Jena, Kiel, Munich, Nuremberg, Oldenburg, Regensburg, Ulm, Wuerzburg
- Age
- 18 év and over
- People
- 45
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07825064EU 2026-525736-42-00Regiszter frissítve: 2026-11-05
2. fázisToborozResearch participation
A study with new methods to monitor newly diagnosed multiple myeloma in participants being treated with a new treatment combination - TAURUS
- Where
- Hamburg, Munich
- Age
- 18 év and over
- People
- 240 worldwide
- Run by
- European Myeloma Network B.V.
See details and how to joinNCT06189833EU 2023-505221-14-00Regiszter frissítve: 2026-11-04
3. fázisToborozTrial-stage medicine
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- Where
- Dresden, Hamburg, Luebeck, Mainz, Mutlangen, Regensburg, Wuerzburg
- Age
- 18 év and over
- People
- 915 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT07222761EU 2024-519504-27-00Regiszter frissítve: 2026-11-04
3. fázisToborozTrial-stage medicine
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Where
- Hamburg, Heidelberg, Oldenburg
- Age
- 18 év and over
- People
- 270 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT07393282EU 2025-523252-31-00Regiszter frissítve: 2026-11-04
2. fázisToborozTrial-stage medicine
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Berlin, Heidelberg, Wuerzburg
- Age
- 18 év and over
- People
- 510 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT04634552EU 2023-504581-29-00Regiszter frissítve: 2026-11-03
3. fázisToborozTrial-stage medicine
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Where
- Berlin, Essen, Halle (Saale), Hamburg, Nuremberg, Tuebingen, Wuerzburg
- Age
- 18 év and over
- People
- 1590 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05552222EU 2023-503442-30-00Regiszter frissítve: 2026-11-03
3. fázisToborozTrial-stage medicine
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Duesseldorf, Heidelberg, Jena, Wuerzburg
- Age
- 18 év and over
- People
- 400 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07258511EU 2025-522007-18-00Regiszter frissítve: 2026-11-03
3. fázisToborozTrial-stage medicine
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
- Where
- Hamm, Würzburg
- Age
- 18 év and over
- People
- 1000 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07665450Regiszter frissítve: 2026-11-03
3. fázisToborozTrial-stage medicine
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Where
- Aachen, Bamberg, Bonn, Dresden, Düsseldorf, Erfurt, Hamburg, Hanover, Kiel, Marburg, München, Traunstein, Tübingen, Weiden, Würzburg
- Age
- 18 év and over
- People
- 810 worldwide
- Run by
- Celgene
See details and how to joinNCT05519085Regiszter frissítve: 2026-10-30
1/2. fázisToborozTrial-stage medicine
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
- Where
- Essen, Freiburg im Breisgau, Hamburg, Heidelberg, Lübeck, Nuremberg, Tübingen, Würzburg
- Age
- 18 év and over
- People
- 226 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06106945EU 2023-508590-89-00Regiszter frissítve: 2026-10-30
3. fázisToborozTrial-stage medicine
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Where
- Berlin, Chemnitz, Hamburg, Hanover, Heidelberg, Kiel, Leipzig, Magdeburg, Munich, Nuremberg, Wuerzburg
- Age
- 18 év and over
- People
- 440 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479EU 2024-515279-37-00Regiszter frissítve: 2026-10-29
3. fázisToborozTrial-stage medicine
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Where
- Aachen, Brunswick, Chemnitz, Freiburg im Breisgau, Hamburg, Mainz, Regensburg, Tuebingen, Ulm
- Age
- 18 év and over
- People
- 1060 worldwide
- Run by
- Pfizer
See details and how to joinNCT05623020EU 2024-514139-50-00Regiszter frissítve: 2026-10-27
1/2. fázisToborozTrial-stage medicine
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Where
- Hamburg, Heidelberg, Munich, Wuerzburg
- Age
- 18 év and over
- People
- 325 worldwide
- Run by
- AbbVie
See details and how to joinNCT06953960EU 2024-517140-65-00Regiszter frissítve: 2026-10-27
1/2. fázisToborozTrial-stage medicine
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
- Where
- Essen, Mainz, Würzburg
- Age
- 18 év and over
- People
- 387 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT03761108EU 2024-511454-45-00Regiszter frissítve: 2026-10-26
1/2. fázisToborozTrial-stage medicine
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Where
- Aachen, Dresden, Hamburg, Wuerzburg
- Age
- 18 év and over
- People
- 246 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT04973605EU 2023-507751-30-00Regiszter frissítve: 2026-10-26
3. fázisToborozTrial-stage medicine
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
- Where
- Berlin, Dresden, Essen, Freiburg im Breisgau, Hamburg, Leipzig, München, Oldenburg
- Age
- 18 év to 130 év
- People
- 750 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07735637Regiszter frissítve: 2026-10-21
3. fázisToborozResearch participation
A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma
- Where
- Bonn, Freiburg im Breisgau, Hamburg, Hanover, Leipzig, Tuebingen
- Age
- 18 év and over
- People
- 206 worldwide
- Run by
- Janssen Cilag International
See details and how to join2025-523815-12-00EU 2025-523815-12-00Regiszter frissítve: 2026-10-19
3. fázisToborozResearch participation
A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
- Where
- Berlin, Greifswald, Hamm, Munich, Tuebingen, Wuerzburg
- Age
- 18 év and over
- People
- 423 worldwide
- Run by
- Janssen Cilag International
See details and how to join2026-526654-14-01EU 2026-526654-14-01Regiszter frissítve: 2026-10-14
3. fázisToborozTrial-stage medicine
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Where
- Giessen, Mainz
- Age
- 18 év and over
- People
- 63 worldwide
- Run by
- CSL Behring
See details and how to joinNCT07648264EU 2026-525626-38-00Regiszter frissítve: 2026-10-14
1/2. fázisToborozTrial-stage medicine
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
- Where
- Frankfurt, Lübeck
- Age
- 18 év and over
- People
- 258 worldwide
- Run by
- Sanofi
See details and how to joinNCT04643002Regiszter frissítve: 2026-10-13
3. fázisToborozTrial-stage medicine
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- Where
- Cologne, Essen, Hamburg
- Age
- 18 év and over
- People
- 183 worldwide
- Run by
- Takeda
See details and how to joinNCT06980480EU 2024-518420-80-00Regiszter frissítve: 2026-10-13
3. fázisToborozTrial-stage medicine
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Where
- Augsburg, Bad Saarow, Berlin, Bonn, Duesseldorf, Frankfurt Am Main, Greifswald, Hamburg, Hamm, Hanover, Kiel, Tuebingen, Wuerzburg
- Age
- 18 év and over
- People
- 380 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07555938EU 2025-524028-23-00Regiszter frissítve: 2026-10-13
3. fázisToborzás még nem indultResearch participation
A trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.
- Where
- Berlin, Dresden, Essen, Hamburg, Leipzig, Munich, Oldenburg
- Age
- 18 év and over
- People
- 249 worldwide
- Run by
- AstraZeneca AB
See details and how to join2026-525367-40-00EU 2026-525367-40-00Regiszter frissítve: 2026-10-12
Minden vizsgálat (Mielóma multiplex) és a térkép
Ez az oldal nem orvosi tanács. Mielőtt egy vizsgálatot megkeresel, beszélj az orvosoddal.